Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus

European Journal of Clinical Pharmacology

Volumn 56, Issue 2, 2000, Pages 129-133

  Walter, Y H ^a   Spratt, D I ^b   Garreffa, S ^a   McLeod, J F ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MAINE MEDICAL CENTER   (United States)

Author keywords

Insulin secretion; Nateglinide; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN; NATEGLINIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0034080007     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050730     Document Type: Article

References (22)

1. 1. Avignon A, Radauceanu A, Monnier L (1997) Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20: 1822-1826
2. 2. Hanefeld M, Temelkova-Kurktschiev T (1997) The postprandial state and the risk of atherosclerosis. Diabet Med 14[suppl 3]: S6-S11
3. 3. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K (1995) Sudden death, impaired glucose tolerance, and diabetes in Japanese-American men. Circulation 91: 2591-2595
4. 4. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J (1997) Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 20: 163-169
5. 5. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M-C, Avogaro A, Tiengo A, Del Prato S (1999) Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48: 99-105
6. 6. Kikuchi M (1996) Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabet Med 13[suppl 6]: S151-S155
7. 7. Dunning BE (1997) New non-sulfonylurea insulin secretagogues. Expert Opinion on Investigational Drugs 6: 1041-1048
8. 8. Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T, Kondo N (1997) Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull 20: 354-359
9. 9. Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, Maki T (1997) Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Br J Pharmacol 120: 137-145
10. 10. Sato Y, Nishikawa M, Shinkai H, Sukegawa E (1991) Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 12: 53-59
11. 11. Akiyoshi M, Kakei M, Nakazaki M, Tanaka H (1995) A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am J Physiol 268: E185-E193
12. 2+ influx. Endocrinology 134: 1395-1400
13. 13. Karara AH, Dunning BE, McLeod JF (1999) The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent A-4166 in healthy subjects. J Clin Pharmacol 39: 172-179
14. 14. Hirschberg Y, Karara A, Pietri AO, McLeod JF (2000) Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin: a randomized, placebo-controlled, crossover study. Diabetes Care 23: 349-353
15. 15. De Souza CJ, Russo P, Lozito R, Dunning B (1997) The metabolic advantages of a rapid onset/short acting insulin secretagogue on prandial glucose excursions (abstract 0925). Diabetes 46[suppl 1]: 241A
16. 16. Hirose H, Maruyama H, Ito K, Seto Y, Kido K, Koyama K, Dan K, Saruta T, Kato R (1994) Effects of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) on insulin and glucagon secretion in isolated perfused rat pancreas. Pharmacology 48: 205-210
17. 17. Hanefeld M, Bouter KP, Dickinson S, Guitard C (2000) Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23: 202-207
18. 18. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617-621
19. 19. Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF (2000) Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 85: 1081-1086
20. 20. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 541-549
21. 21. Seltzer HS (1989) Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am 18: 163-183
22. 22. Ferner RE, Neil HAW (1988) Sulphonylureas and hypoglycaemia. BMJ 296: 949-950